Posted by Michael Wonder on 15 Jan 2020
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
15 January 2020 - Cost-effectiveness watchdog issues a round of draft and final guidance.
The UK’s National Institute for Health and Care Excellence has issued a round of draft and final guidance on a number of key cancer drugs, with winners and losers across the board.
